Profil
Fanny Cavalié is Chief Executive Officer at NorthLinks Bio, Inc. starting in 2026.
Former positions include Head-Multiple Sclerosis Portfolio Strategy at Biogen, Inc. from 2014 to 2018, Associate Partner at McKinsey & Co., Inc. (United Kingdom) from 2003 to 2014, and Chief Strategy & Business Operations Officer at Foghorn Therapeutics, Inc. Education includes an MBA from École des Hautes Études Commerciales de Paris, conferred in 2001.
Postes actifs de Fanny Cavalié
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Fanny Cavalié
| Sociétés | Poste | Fin |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Directeur des opérations | 01/07/2024 |
| BIOGEN INC. | Corporate Officer/Principal | 01/03/2018 |
McKinsey & Co., Inc. (United Kingdom)
McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Provides investment advisory services | Corporate Officer/Principal | 01/05/2014 |
Formation de Fanny Cavalié
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
École des Hautes Études Commerciales de Paris
École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McKinsey & Co., Inc. (United Kingdom)
McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Provides investment advisory services | Finance |
Foghorn Therapeutics, Inc.
Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
















